58
Participants
Start Date
January 9, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
June 30, 2028
NRT6008 Injection + Systematic chemotherapy
"-Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and selected tumor average absorbed dose."
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Second Affiliated Hospital of Soochow University, Suzhou
RECRUITING
Shanghai Changhai Hospital, Shanghai
RECRUITING
Shanghai General Hospital, Shanghai
RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
Tianjin Medical University General Hospital, Tianjin
Chengdu New Radiomedicine Technology Co. LTD.
INDUSTRY